Drugs that contain Methotrexate
1. List of Otrexup drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562564 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US11446441 | OTTER PHARMS | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US9533102 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9629959 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8021335 | OTTER PHARMS | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US9867949 | OTTER PHARMS | Injector safety device |
Mar, 2029
(5 years from now) | |
| US10709844 | OTTER PHARMS | Injector safety device |
Mar, 2029
(5 years from now) | |
| US11497753 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US8579865 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US8945063 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US9421333 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US8480631 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(7 years from now) | |
| US8814834 | OTTER PHARMS | Injector safety device |
May, 2031
(8 years from now) | |
Market Authorisation Date: 11 October, 2013
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
OTREXUP family patents
30
United States
6
European Union
5
Japan
4
Spain
3
Canada
2
Korea, Republic of
2
China
1
Portugal
1
Hungary
1
Israel
1
Australia
1
Denmark
1
Brazil
2. List of Rasuvo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8664231 | MEDEXUS | Concentrated methotrexate solutions |
Jun, 2029
(6 years from now) | |
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
RASUVO family patents
8
United States
3
Germany
3
European Union
2
Austria
2
Canada
1
Portugal
1
Russia
1
Spain
1
Brazil
1
Croatia
1
Mexico
1
Korea, Republic of
1
Japan
1
Cyprus
1
Slovenia
1
ME
1
Ukraine
1
Poland
1
Australia
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic